Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Short position
Paradigm Biopharmaceuticals (ASX:PAR) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 593,492 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.09 percentage points. Its highest recorded short interest was 4.77% in March 2022. PAR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Paradigm Biopharmaceuticals (PAR) company profile
Profile, insiders and operations
PAR intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links